Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Single-Cell Analysis Sheds Light on Leukemia Cell Heterogeneity

Chromosomal instability plays a crucial role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM and the European Molecular Biology Laboratory (EMBL) used state-of-the-art single-cell analysis methods to analyze the cellular heterogeneity of a specific form of acute myeloid leukemia.

26 Nov 2024

Study Links Extracellular Vesicles to Blood Vessel Damage in Cancer

A landmark study led by WEHI and La Trobe University has found a potential new diagnostic marker that could be used to better detect the level of tissue damage in our bodies.

29 Oct 2024

Scientists Discover How AML Cells Use P-Bodies to Sustain Growth

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth.

22 Aug 2024

The Protein STAT3 Helps the Immune System Fight Leukemia

Study at the Karl Landsteiner University of Health Sciences uncovers unknown interaction between leukemic cells and immune cells. Potential biomarkers for future immunotherapies found.

From Karl Landsteiner University of Health Sciences 17 Jul 2024

3D Cell Cultures Improve Drug Screening Accuracy but Show Lower Efficacy for Anti-Cancer Drugs

The existing knowledge on monolayers and spheroid-based cell cultures, including the constituent compounds, and the difference in efficacy during drug screening, especially for anti-cancer drugs targeting cytoskeletal dynamics and cell cycles.

21 Jun 2024

Syntekabio to Unveil Novel Biologics Platform at 20th Annual PEGS Boston Summit

Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, where the company will highlight its novel biologics platform. The event is being held May 13-17, 2024 at the Omni Hotel at the Seaport, Boston, MA.

11 May 2024

U of T Researchers Develop Groundbreaking Platform for Protein-Based Disease Treatment

Researchers at the University of Toronto and Sinai Health have created a new platform to identify proteins that can be co-opted to control the stability of other proteins -; a new but largely unrealized approach to the treatment of disease.

25 Mar 2024

Study Elucidates How Mutant NPM1 Protein Drives Leukemia by Activating Autophagy System

In a recent study, scientists led by Professor Stefan Müller from Goethe University's Institute of Biochemistry II investigated a specific form of blood cancer known as acute myeloid leukemia, or AML.

5 Dec 2023

Wilmot Researchers Uncover a "Genomic Tug of War" That Influences Decitabine's Effectiveness

Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's effects or become resistant over time.

17 Nov 2023

Novel Activation Mechanism for First Identified Oncogene

In the late 1970s, the link between the c-Src gene and cancer was unveiled, marking the identification of the inaugural oncogene.

1 Nov 2023

Mechanisms of MCL-1 Inhibitor-Induced MCL-1 Protein Upregulation and Induction of Apoptosis

A new editorial paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, "Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability."

29 Jun 2023

Cell Fate Conversion Plays Crucial Role in Cancer Research

Researchers from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Berlin and the Centre for Genomic Regulation (CRG) in Barcelona have discovered how cells speed changes to their identity known as “cell fate conversion.”

28 Jun 2023

CloneTracer Reveals a Differentiation Landscape of Acute Myeloid Leukemia

Researchers have developed a new method to distinguish between cancerous and healthy stem cells and progenitor cells from samples of patients with acute myeloid leukemia (AML), a disease driven by malignant blood stem cells that have historically been difficult to identify.

25 Apr 2023

New Epigenetic Vulnerability Of Acute Myeloid Leukemia Revealed

Acute myeloid leukemia (AML) is an aggressive blood cancer that causes uncontrolled accumulation of white blood cells. Because of the poor outcomes of this disease, researchers across the globe have been on the hunt for new ways to treat AML, while preserving normal blood development.

10 Apr 2023

Previously unknown telomere and cancer connection to the immune system revealed

Johns Hopkins Medicine scientists say their 20-year study of more than 200 people with premature aging syndromes caused by abnormally short telomeres, or shortened repetitive DNA sequences at the ends of chromosomes, may upend long-held scientific dogma and settle conflicting studies about how and whether short telomeres contribute to cancer risk.

31 Mar 2023

Potential therapeutic can synergize with existing drugs to effectively destroy leukemia cells

A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells.

9 Mar 2023

Study pinpoints a splicing deregulation that causes therapeutic vulnerability in pediatric AML

Pediatric acute myeloid leukemia or pAML is a childhood blood cancer, one that has proved confounding to clinicians and researchers, with a high relapse rate and relatively few identified genetic mutations (compared to the adult version) that might explain its cause.

8 Mar 2023

Developing a potential drug molecule that targets STAT5

STAT5 has generally been recognized as an enticing cancer target, but after years of research, it was downgraded to the “undruggable” category. Now, scientists at the University of Michigan Rogel Cancer Center have achieved success with a novel approach.

17 Feb 2023

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.